Please find attached the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30-06-2025 along with Auditors'' Limited Review Report.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma reported a strong Q1 FY26 with standalone revenue from operations rising about 40% year-on-year to ₹14,231.10 lakhs (vs ₹10,172.38 lakhs in Q1 FY25), though down sequentially from ₹16,156.81 lakhs in Q4 FY25. The company swung to a standalone net profit of ₹373.28 lakhs from a loss of ₹117.95 lakhs in the year-ago quarter, with basic EPS of ₹0.15 versus ₹(0.05) earlier. Consolidated revenue grew even faster at roughly 46% YoY to ₹14,526.16 lakhs, delivering a consolidated net profit of ₹395.85 lakhs versus a ₹120.74 lakh loss last year. The auditor (NGST & Associates) issued an unmodified limited review opinion on both sets of results, and the company noted this is the first quarter under Ind AS (voluntarily adopted with 1 April 2024 transition date), with prior periods restated. Two subsidiaries were acquired during the quarter – 51% of Ishwari Healthcare (₹1.5 cr) and 100% of Dubai-based Cibachem General Trading LLC (₹55 lakhs).
Positive for shareholders: sharp YoY revenue growth and a clear turnaround from loss to profit suggest improving operating performance, though the sequential decline from Q4 FY25 and rising finance costs (₹571.30 lakhs vs ₹376.73 lakhs YoY) warrant monitoring. The acquisitions and pending Dubai court award (~₹9.19 crore) could provide future upside, but standalone PBT margin remains thin at around 3.6%.